Pharmaceuticals

Brexit: EMA’s regulatory guidance on centrally approved medicinal products – the present state of play

Jacqueline Bore

The champagne bottles have been drained in Amsterdam and tears dried in Milan and Bratislava but the serious work of mapping out the practical implications of Brexit continues at the European Medicines Agency (EMA). The EMA and the European Commission issued a Notice in May 2017 confirming that “unless the withdrawal agreement establishes another date” Read More

Dutch Minister to explore possibility of compulsory licenses and pharmacy preparations

Anna-Maria Withagen

The Dutch Minister of Medical Care, Bruno Bruins, announced that he is going to explore the possibility of granting compulsory licenses in order to make pharmaceutical companies lower the prices of certain medicines they offer. During a debate, Bruins said that, although the instrument has not been used in the previous years, this does not Read More

Pension funds to catalyse growth in Life Sciences companies?

Matthew Appleton

We’ve seen a lot of activity in the past week around how the UK government plans to galvanise growth in innovative companies (summary here). As I wrote a couple of months ago, only by focusing on all stages in the growth cycle of a Life Sciences company can four £20bn+ UK companies be created in Read More

EU Competitiveness Council to review Current Status of the Unitary Patent and Unified Patent Court

Laëtitia Bénard

The Council of the European Union has published a note, from the Presidency to the Council, entitled “Unitary Patent and Unified Patent Court – Information from the Presidency on the state of play”. The note relates to the upcoming meeting of the Competitiveness Council on 30 November, and explains as follows: “The Presidency will give Read More

French Competition Authority launches sector inquiry into medicinal products and biomedical laboratories

Patricia Carmona Botana

On 20 November 2017, the French Competition Authority (FCA) launched a sector inquiry into medicinal products and medical biology (biomedical) laboratories in France.  As previously announced, the inquiry aims to address the challenges that the sector entails for the French insurance system and public health and to assess the feasibility of more competitive conditions with Read More